Remedium Lifecare Ltd. , a prominent player in the pharmaceutical supply chain and specialty chemicals sector, has announced significant changes to its leadership team. The company has appointed Mr. Vignesh Laxman Gawde as Whole-Time Director and Mr. Rambhajan Vishwakarma as Independent Director, in a move aimed at enhancing its leadership and promoting growth in the pharmaceutical sector.

Strategic Appointments

The appointments come at a crucial time for Remedium Lifecare as it seeks to accelerate its growth momentum. Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., expressed confidence in the new appointments, stating, "Mr. Gawde's deep technical expertise in the pharmaceutical field and Mr. Vishwakarma's vast experience in the financial sector will bring a strong strategic balance to our leadership team."

Expertise and Experience

Mr. Gawde, with his extensive background in pharmaceutical research, is expected to focus on strengthening R&D, quality assurance, and innovation. His expertise aligns with Remedium Lifecare's expansion plans across key therapeutic areas, including anti-infectives, cardiovascular, and CNS treatments.

Mr. Vishwakarma's appointment as Independent Director is aimed at enhancing corporate governance, transparency, and financial oversight. His experience in the financial sector is expected to support Remedium Lifecare's financial prudence and growth strategy.

Future Outlook

These strategic appointments underscore Remedium Lifecare's commitment to building a robust, future-ready leadership structure. The company anticipates that the combined experience of Mr. Gawde and Mr. Vishwakarma will drive its next phase of expansion, enhancing R&D capabilities, strengthening operational efficiencies, and deepening market presence across domestic and global geographies.

As Remedium Lifecare continues to evolve in the pharmaceutical and specialty chemicals space, these leadership changes signal the company's focus on innovation, quality, and strategic growth. The company remains dedicated to developing and distributing advanced healthcare solutions, with a growing emphasis on R&D, CDMO services, and international expansion.

Remedium Lifecare Limited has officially completed its transformation to Supha Pharmachem Limited following approval from the Ministry of Corporate Affairs. The pharmaceutical company, which specializes in Active Pharmaceutical Ingredients (APIs) and intermediates, received the Certificate of Incorporation pursuant to change of name on December 15, 2025.

Official Name Change Approval

The Office of the Central Processing Centre, Ministry of Corporate Affairs, issued the Certificate of Incorporation pursuant to change of name on December 15, 2025. The company has been officially renamed from Remedium Lifecare Limited to Supha Pharmachem Limited with effect from December 15, 2025.

Shareholder Approval Background

Prior to the official approval, shareholders had overwhelmingly supported the name change through a postal ballot, with over 97.00% approval. The special resolution was part of three key resolutions that also included important board appointments.

New Board Leadership

Alongside the name change, the company confirmed two significant board appointments:

Executive Leadership

Mr. Vignesh Laxman Gawde was appointed as Executive Director for a five-year term. Mr. Gawde holds an M.Sc. in Physical Chemistry from the Institute of Science, Mumbai University.

Board Chairman

Mr. Rambhajan Vishwakarma was appointed as Non-Executive Director and Chairman of the Board, bringing over 15 years of experience in banking product sales.

Implementation and Next Steps

The company has informed BSE Limited about the official name change and will process the necessary applications with the stock exchange. All company records and documents will be updated to reflect the new name - Supha Pharmachem Limited. As per regulatory requirements, the company must display both the old and new names at all required locations for a period of two years.

Corporate Details

The successful completion of the name change to Supha Pharmachem Limited represents a significant milestone in the company's evolution, potentially signaling a new strategic direction in the pharmaceutical industry.